We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
-$325M
Cap. Flow
-$296M
Cap. Flow %
-19.34%
Top 10 Hldgs %
65.86%
Holding
300
New
43
Increased
68
Reduced
83
Closed
84

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.6M
2
TSRO
TESARO, Inc.
TSRO
+$7.45M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$5.41M
4
MBOT icon
Microbot Medical
MBOT
+$4.73M
5
UTHR icon
United Therapeutics
UTHR
+$4.46M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$6.09M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.39M
3
MTFB
Motif Bio plc ADRs
MTFB
+$4.6M
4
OTIC
Otonomy, Inc.
OTIC
+$3.19M
5
PALI icon
Palisade Bio
PALI
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 13%
2 Materials 0.27%
3 Financials 0.11%
4 Consumer Staples 0.03%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONSIZ
151
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$428K 0.03%
500,624
-429,648
-46% -$78.2K
STML
152
PUT
DELISTED
Stemline Therapeutics, Inc.
STML
$415K 0.03%
451
+79
+21% +$659
RCKT icon
153
Rocket Pharmaceuticals
RCKT
$344M
$404K 0.03%
53,163
+27,930
+111% +$208K
RXIIW
154
DELISTED
RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021
RXIIW
$400K 0.03%
2,220,492
-17,995
-0.8% -$3.53K
ADYX
155
DELISTED
Adynxx Inc
ADYX
$396K 0.03%
17,857
-17,661
-50% -$415K
VIRX
156
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$395K 0.03%
4,175
-230
-5% -$26.4K
GEVO icon
157
Gevo
GEVO
$363M
$390K 0.03%
28,266
-29,172
-51% -$501K
SLS icon
158
CALL
SELLAS Life Sciences
SLS
$2.01B
$353K 0.02%
4
– –
ARAV
159
CALL
DELISTED
Aravive, Inc. Common Stock
ARAV
$351K 0.02%
34
-6
-15% -$644
SCMP
160
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$349K 0.02%
33,200
-51,800
-61% -$528K
ARRY
161
CALL
DELISTED
Array Biopharma Inc
ARRY
$333K 0.02%
+398
New +$3.25K
ATRS
162
CALL
DELISTED
Antares Pharma, Inc.
ATRS
$327K 0.02%
+1,016
New +$2.88K
EDIT icon
163
CALL
Editas Medicine
EDIT
$404M
$291K 0.02%
881
+97
+12% +$1.75K
ONTXW
164
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$290K 0.02%
645,350
-5,400
-0.8% -$3.25K
ONSIW
165
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$277K 0.02%
338,113
-592,479
-64% -$292K
ADVM
166
DELISTED
Adverum Biotechnologies
ADVM
$275K 0.02%
11,000
-17,263
-61% -$472K
ADXS
167
PUT
DELISTED
Advaxis Inc
ADXS
$269K 0.02%
28
– –
GPL
168
PUT
DELISTED
Great Panther Mining Limited
GPL
$266K 0.02%
208
+6
+3% +$77
MTFBW
169
DELISTED
Motif Bio plc Warrants to Purchase ADRs
MTFBW
$256K 0.02%
141,334
-270,038
-66% -$527K
OTIC
170
PUT
DELISTED
Otonomy, Inc.
OTIC
$245K 0.02%
130
– –
PTN
171
Palatin Technologies
PTN
$15.1M
$238K 0.02%
443
-1,178
-73% -$564K
SGLBW
172
DELISTED
Sigma Labs, Inc. Warrant
SGLBW
$225K 0.01%
247,759
-2,241
-0.9% -$2.18K
IMNN icon
173
Imunon
IMNN
$6.35M
$223K 0.01%
+556
New +$355K
SRPT icon
174
PUT
Sarepta Therapeutics
SRPT
$1.63B
$222K 0.01%
+66
New +$2.15K
NTRP icon
175
NextTrip
NTRP
$24.3M
$220K 0.01%
515
-396
-43% -$206K
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sabby Management held 300 positions worth $1.53B, down 18% from $1.85B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $296M in Q2 2017, closing 84 positions and reducing 83 holdings. Its most notable exit was Amgen, an estimated $6.09M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 6.3% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in TESARO, Inc. worth $7.19M.

  • Sabby Management's largest Q2 2017 buy was TESARO, Inc.: 51,426 shares worth $7.19M.
  • Sabby Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $95.6M increase.
  • Sabby Management's biggest Q2 2017 reduction was Otonomy, Inc., cutting an estimated $3.19M.
  • Sabby Management fully exited Amgen in Q2 2017, selling an estimated $6.09M.
  • Sabby Management's ten largest holdings make up 66% of its $1.53B portfolio in Q2 2017.
  • Sabby Management opened 43 new positions and closed 84 in Q2 2017.
  • Sabby Management's portfolio value fell 18% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.